Success of Transitioning Uncontrolled Glaucoma Patients From Prior Mono or Adjunctive Therapy to DuoTrav

Alcon

Status and phase: Completed; Phase 4

Conditions: Glaucoma

Treatments: Drug: Travoprost 0.004%/timolol maleate 0.5% fixed combination ophthalmic solution (DuoTrav)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00519753

CMS-06-12

Details and patient eligibility

About

The purpose of this study is to assess the safety and efficacy of transitioning uncontrolled glaucoma patients to DuoTrav from other mono or adjunctive therapies.

Enrollment: 522 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults with primary open-angle glaucoma, ocular hypertension or pigment dispersion glaucoma.
• Other protocol-defined inclusion criteria may apply.

Exclusion criteria

• Age related.
• Other protocol-defined exclusion criteria may apply.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

522 participants in 1 patient group

DuoTrav

Experimental group

Description:

One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks

Treatment:

Drug: Travoprost 0.004%/timolol maleate 0.5% fixed combination ophthalmic solution (DuoTrav)